“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
What started as one man’s journey and his belief in the virtue of his cause, has paved the path for Lupin to become a global pharmaceutical major.
Lupin began as one man’s dream of creating a better world. Dr. Desh Bandhu Gupta, lovingly known as DBG, believed in the idea of ‘simple living and high thinking’ and aspired to put India on the global pharmaceuticals map. DBG’s legacy is one of performance, values and public spiritedness. At 50, Lupin is a strong and vast fabric woven in his strong values adopted by the passionate team of professionals working to offer medicines and researching through our global web of laboratories to build and grow in the world of pharmaceuticals.
When Dr. Gupta started Lupin in 1968, his wife, Mrs. Manju Gupta, served as his first investor with an investment of INR 5,000. To DBG, Lupin was a weapon to fight life-threatening diseases that plagued his nation. Today, Lupin has successful operations in over 100 countries and it is largely because of the culture of innovation, unyielding integrity, and world-class operations that DBG pioneered. But DBG’s true genius as an entrepreneur lay in bringing out the best in every person he met.
Business to him was sacred and he operated with the highest ethical standards, professionalism and respect.
Over the past 50 years, with DBG at the helm of affairs, Lupin saw both struggles and victories. But his personality encouraged learning from the experiences and never rest on laurels. He inspired the team to move ahead, set high targets and meet one’s goals through unyielding commitment to compliance and integrity. He had a compelling vision of the future and strived to light the path of glory.
As we look forward to our altruistic heritage as a world leader, DBG’s vision guides us. He often stated, “Dreaming big is not enough, you must convert these dreams into real actionable plans. You must challenge yourself to seek excellence and to innovate; to continuously connect vision, strategy and execution. That is what makes a company great and go beyond mere growth”.
Of all the hats, he wore in his lifetime, DBG was most happy to have contributed to creating a more inclusive society – one that provides opportunities to all who need them. He was always proud of being an Indian who contributed to the nation-building process.
Lupin has navigated the market without losing sight of his vision. As we look to our 50 year’s journey, we continue to be inspired by DBG’s guiding tenets: to focus on research to be a growth driver; to make technology a differentiator to achieve world-class manufacturing standards; to focus on quality; make people our strength – bringing and retaining the right people on board, giving them autonomy and enabling them to succeed; caring for people and all our stakeholders; always focus on affordable high-quality healthcare, especially in areas of unmet needs.
Today, we are truly a multinational pharmaceutical company focused on meaningful and differentiated product portfolio comprising of Complex Generics, Biosimilars and Specialty Products. As we continue the journey started in 1968, we commit to the legacy that is our honour to uphold.
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.